» Articles » PMID: 14762782

Severity of Inflammation is a Risk Factor for Colorectal Neoplasia in Ulcerative Colitis

Overview
Specialty Gastroenterology
Date 2004 Feb 6
PMID 14762782
Citations 400
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Patients with ulcerative colitis are at increased risk of colorectal cancer. It is widely believed that this is secondary to colonic inflammation. However, the severity of colonic inflammation has never been shown to be a risk factor.

Methods: We devised a case-control study of patients with long-standing extensive ulcerative colitis to examine various potential risk factors for neoplasia. All cases of colorectal neoplasia detected from our surveillance program between January 1, 1988, and January 1, 2002, were studied (n = 68). Each patient was matched with 2 control patients from the same surveillance population (n = 136). Matching was for sex, colitis extent, age at onset, duration of colitis, and year of index surveillance colonoscopy. Segmental colonoscopic and histological inflammation was recorded by using a simple score (0, normal; 1, quiescent/chronic inflammation; and 2, 3, and 4, mild, moderate, and severe active inflammation, respectively). Other data collected included history of primary sclerosing cholangitis, family history of colorectal cancer, and smoking and drug history (mesalamine 5-aminosalicylic acid, azathioprine, and folate).

Results: Univariate analysis showed a highly significant correlation between the colonoscopic (odds ratio, 2.5; P = 0.001) and histological (odds ratio, 5.1; P < 0.001) inflammation scores and the risk of colorectal neoplasia. No other factors reached statistical significance. On multivariate analysis, only the histological inflammation score remained significant (odds ratio, 4.7; P < 0.001).

Conclusions: In long-standing extensive ulcerative colitis, the severity of colonic inflammation is an important determinant of the risk of colorectal neoplasia. Endoscopic and histological grading of inflammation could allow better risk stratification for surveillance programs.

Citing Articles

Colitis-Associated Dysplasia in Inflammatory Bowel Disease: Features and Endoscopic Management.

Schiavone S, Biancone L, Fiorillo M, Divizia A, Mancone R, Neri B Cancers (Basel). 2025; 17(5).

PMID: 40075631 PMC: 11899620. DOI: 10.3390/cancers17050784.


Colorectal Neoplasia in Inflammatory Bowel Disease.

Al Sulais E, AlAmeel T, Alenzi M, Shehab M, AlMutairdi A, Al-Bawardy B Cancers (Basel). 2025; 17(4).

PMID: 40002259 PMC: 11853504. DOI: 10.3390/cancers17040665.


A transcriptomic score to classify the inflammation-dysplasia-cancer sequence lesions in inflammatory bowel disease.

Cremer A, Rosewick N, Kelsey M, Trepo E, Libert F, De Vos M J Crohns Colitis. 2025; 19(3).

PMID: 39945142 PMC: 11904305. DOI: 10.1093/ecco-jcc/jjaf026.


Outcomes of oral vancomycin therapy in children with atypical ulcerative colitis with or without confirmed primary sclerosing cholangitis: a real-world observational study.

Raisanen L, Balouch F, McLaren-Kennedy A, Clark J, Lewindon P BMJ Open Gastroenterol. 2025; 12(1).

PMID: 39938966 PMC: 11822383. DOI: 10.1136/bmjgast-2024-001605.


Antitumor Effects of Tryptanthrin on Colorectal Cancer by Regulating the Mitogen-Activated Protein Kinase Signaling Pathway and Targeting Topo I and IDO1.

Lu S, Hou B, Wang T, Ma K, Huang A, Wu X ACS Omega. 2025; 10(3):3206-3221.

PMID: 39895716 PMC: 11780470. DOI: 10.1021/acsomega.4c11189.